July 29, 2020
Takeda R&D has aligned around a set of guiding principles that inform our decisions and actions, in response to the COVID-19 pandemic:
Takeda & Clinical Trial Activities
As always, Takeda is committed to ensuring the integrity of our global clinical trials while safeguarding the many patients, healthcare providers, employees and other partners who participate in our studies. We are dedicated to protecting global public health and appreciate the extraordinary circumstances under which investigators and site staff around the world are operating clinical studies while managing the additional burdens caused by COVID-19.
Due to the global impact of COVID-19, Takeda had placed a temporary pause on the initiation of new studies with the exception of potential treatments for CoVIg-19, including the investigational plasma-derived therapy for COVID-19. For already ongoing studies we had temporarily paused the activation of new study sites and new patient enrollment with a small number of exceptions. This was a short-term action and we have now been able to resume recruitment in the majority of our studies at least at some sites and countries.
Given the fluidity of the pandemic, we are evaluating each trial on a fit-for-purpose basis taking into consideration the varying impact of COVID-19 in different regions of the world. Where possible, Takeda worked quickly and creatively implement solutions such as direct to patient delivery of study medicines and the re-evaluation of trial design to account for potential disruptions. We continue to assess and build out digital technologies to enable remote monitoring of patients enrolled in clinical trials.